Prana receives Orphan Designation for PBT434 for treatment of MSA
Prana receives first orphan drug designation from the FDA for the treatment of Multiple System Atrophy
Dr David Stamler’s Biotech Showcase Presentation
Prana Presents at Biotech Showcase
Prana’s Chief Medical Officer Dr David Stamler, MD will present at the Biotech Showcase in San Francisco on Monday 7th January, US Pacific Standard Time.
Life Biosciences LLC leads strategic investment of up to A$44.5 million in Prana
Prana Biotechnology has today announced that it has entered into a securities purchase agreement for a lead investment by Boston based Life Biosciences LLC (“Life Biosciences”) to raise up to approximately A$44.5 million
Prana Biotechnology 2018 AGM Presentation
Prana AGM Investor Conference Call
Prana invites investors unable to attend the Company’s Annual General Meeting to participate via teleconference.
Pre-clinical evidence demonstrates PBT434 as a potential treatment for MSA
PBT434 prevents alpha-synuclein aggregation, preserves neurons, reduces glial cell inclusions and slows motor dysfunction in an animal model of Multiple System Atrophy
Link to XBRL Interactive Data 30 June 2018
PBT434 data to be presented at the International Congress of Parkinson’s Disease and Movement Disorders
Prana’s PBT434 prevents neuronal loss in a new model of neurodegeneration